title: Thalidomide as salvage therapy for chronic graft-versus-host disease.
abstract: Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or PSE and cyclosporine (CSA) were treated with thalidomide. Sixteen patients (20%) had a sustained response, 9 with a complete remission and 7 with a partial response. Twenty-nine patients (36%) had thalidomide discontinued because of side effects, which included sedation, constipation, neuritis, skin rash, and neutropenia. Side effects were reversible with drug discontinuation except for mild residual neuritis in one case. Rashes and neutropenia have not previously been reported as thalidomide side effects when used for CGVHD treatment. We conclude thalidomide is immunosuppressive and active in the treatment of CGVHD. A high incidence of reversible side effects limited dose intensity and reduced the number of patients who could benefit from treatment.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Parker
authors.forename: N
authors.initials: N
authors.lastname: Chao
authors.forename: A
authors.initials: A
authors.lastname: Nademanee
authors.forename: M R
authors.initials: MR
authors.lastname: O'Donnell
authors.forename: G M
authors.initials: GM
authors.lastname: Schmidt
authors.forename: D S
authors.initials: DS
authors.lastname: Snyder
authors.forename: A S
authors.initials: AS
authors.lastname: Stein
authors.forename: E P
authors.initials: EP
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Molina
authors.forename: D E
authors.initials: DE
authors.lastname: Stepan
authors.forename: A
authors.initials: A
authors.lastname: Kashyap
authors.forename: I
authors.initials: I
authors.lastname: Planas
authors.forename: R
authors.initials: R
authors.lastname: Spielberger
authors.forename: G
authors.initials: G
authors.lastname: Somlo
authors.forename: K
authors.initials: K
authors.lastname: Margolin
authors.forename: K
authors.initials: K
authors.lastname: Zwingenberger
authors.forename: K
authors.initials: K
authors.lastname: Wilsman
authors.forename: R S
authors.initials: RS
authors.lastname: Negrin
authors.forename: G D
authors.initials: GD
authors.lastname: Long
authors.forename: J C
authors.initials: JC
authors.lastname: Niland
authors.forename: K G
authors.initials: KG
authors.lastname: Blume
authors.forename: S J
authors.initials: SJ
authors.lastname: Forman
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002648:Child; D002908:Chronic Disease; D003248:Constipation / Q000139:chemically induced; D016572:Cyclosporine / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000401:mortality; D006402:Hematologic Diseases / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007239:Infections / Q000401:mortality; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009443:Neuritis / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced*; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide; D016572:Cyclosporine; D011241:Prednisone